All In Biotech

Drug Trial Radar · NCT05309421

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Sep 19, 2022

Primary completion

Apr 7, 2026

Study completion Apr 7, 2026

Sponsor

Lead sponsor
Evaxion Biotech A/SIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Apr 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.

Conditions

  • Melanoma Stage IV
  • Unresectable Melanoma

Interventions

  • EVX-01Drug

    Investigational drug given in combination with standard of care

  • Pembrolizumab 25 MG/MLDrug

    Standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the best overall response (BOR)Time frame: Measurements at Baseline through study completion (up to 102 weeks)

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia

  • One Clinical Research

    Nedlands, Western Australia, Australia

  • Divisione di Oncologia Medica del Melanoma

    Milan, Italy, Italy

  • Instituto Nazionale Tumori IRCCS Fondazione

    Naples, Italy, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.